Gildan Activewear Inc. Stock Rises Friday, Still Underperforms Market
Dow Jones2026/10/09 20:32This article was automatically generated by MarketWatch using technology from Automated Insights. Shares of Gildan Activewear Inc. GIL inched 0.55% higher to C$59.82 Friday, in what proved to be an all-around positive trading session for the Canadian market, with the S&P/TSX Composite Index rising 1.48% to 35,664.62. Gildan Activewear Inc. closed 40.4% short of its 52-week high of C$100.44, which the company achieved on February 13th. Trading volume of 391,192 shares remained below its 50-day average volume of 754,248. Data source: Dow Jones Market Data, FactSet. Data compiled October 9, 2026. This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal. (END) Dow Jones Newswires October 09, 2026 16:32 ET (20:32 GMT)
This article was automatically generated by MarketWatch using technology from Automated Insights.
Shares of Gildan Activewear Inc. GIL inched 0.55% higher to C$59.82 Friday, in what proved to be an all-around positive trading session for the Canadian market, with the S&P/TSX Composite Index rising 1.48% to 35,664.62.
Gildan Activewear Inc. closed 40.4% short of its 52-week high of C$100.44, which the company achieved on February 13th.
Trading volume of 391,192 shares remained below its 50-day average volume of 754,248.
Data source: Dow Jones Market Data, FactSet. Data compiled October 9, 2026.
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
October 09, 2026 16:32 ET (20:32 GMT)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Former BioNTech executive leads Bambusa Therapeutics (BBTX.US) in sprint to Nasdaq, "boosting" eczema drug trials
Bambusa Therapeutics Inc. has filed for an initial public offering, planning to raise funds for clinical trials of treatments for eczema and other inflammatory diseases.
JPMorgan raises AbbVie target price to $300